Sean Lee CFA, an analyst from H.C. Wainwright, reiterated the Buy rating on Prime Medicine, Inc. (PRME – Research Report). The associated price target remains the same with $10.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sean Lee CFA has given his Buy rating due to a combination of factors surrounding Prime Medicine, Inc.’s promising advancements in gene editing technology. The company’s lead product candidate, PM359, is expected to demonstrate proof of concept for prime editing in the treatment of chronic granulomatous disease (CGD). The anticipated clinical data from the ongoing Phase 1/2 study in 2025 could highlight the clinical potential of prime editing, potentially acting as a catalyst for the stock.
Additionally, Prime Medicine’s expansion into the in vivo liver franchise with a new program targeting alpha-1 antitrypsin deficiency (AATD) and the advancement of their drug candidate for Wilson’s Disease (WD) further strengthen their pipeline. The unmet needs in these areas and the promising preclinical data suggest significant market opportunities. Despite the financial loss reported in 1Q25, the company’s cash reserves are deemed sufficient to support operations into the first half of 2026, providing a stable financial outlook.